Literature DB >> 20723992

Interobserver agreement and intraobserver reproducibility of the subjective determination of glaucomatous visual field progression.

Angelo P Tanna1, Jagadeesh R Bandi, Donald L Budenz, William J Feuer, Robert M Feldman, Leon W Herndon, Douglas J Rhee, Julia Whiteside-de Vos.   

Abstract

PURPOSE: To determine the extent of interobserver agreement and intraobserver reproducibility of the subjective determination of visual field progression with achromatic automated static perimetry in eyes with glaucoma, and to determine the impact of access to Glaucoma Progression Analysis (GPA) data on interobserver agreement.
DESIGN: Retrospective, observational case series. PARTICIPANTS: Five glaucoma subspecialists from 5 different academic medical centers.
METHODS: Five visual field tests from each of 100 eyes of 83 patients being monitored for glaucoma were retrospectively identified and subjectively and independently evaluated by the 5 glaucoma subspecialists. Each set of visual fields was classified regarding progression as "none," "questionable," "probable," or "definite." More than 1 month later, the same expert observers reevaluated the same sets of visual field tests to allow determination of intraobserver reproducibility. A final subjective evaluation regarding progression was performed 3 months later, at which time the expert observers had access to the GPA printout. MAIN OUTCOME MEASURES: The level of interobserver agreement and intraobserver reproducibility was estimated using kappa statistics on the raw classification data and also on dichotomized data in which "none" and "questionable" progression were reclassified together as nonprogressed and " probable" and "definite" were reclassified as progressed.
RESULTS: Intraobserver reproducibility was good to excellent (kappa = 0.62-0.78) for the raw data and moderate to good (kappa = 0.58-0.71) for the dichotomized data. Interobserver agreement was moderate (kappa = 0.45; 95% confidence interval [CI], 0.35-0.55) for the raw classification data and also for dichotomized data (kappa = 0.55; 95% CI, 0.46-0.64). Access to the GPA printout did not significantly change the level of interobserver agreement.
CONCLUSIONS: Five glaucoma experts had good to excellent reproducibility of the determination of visual field progression compared with earlier evaluation of the same field sets. Agreement among the experts with each other was only moderate, and did not improve when each had access to GPA results. .
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20723992     DOI: 10.1016/j.ophtha.2010.04.038

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

1.  Agreement and Predictors of Discordance of 6 Visual Field Progression Algorithms.

Authors:  Osamah J Saeedi; Tobias Elze; Loris D'Acunto; Ramya Swamy; Vikram Hegde; Surabhi Gupta; Amin Venjara; Joby Tsai; Jonathan S Myers; Sarah R Wellik; Carlos Gustavo De Moraes; Louis R Pasquale; Lucy Q Shen; Michael V Boland
Journal:  Ophthalmology       Date:  2019-02-04       Impact factor: 12.079

Review 2.  Functional assessment of glaucoma: Uncovering progression.

Authors:  Rongrong Hu; Lyne Racette; Kelly S Chen; Chris A Johnson
Journal:  Surv Ophthalmol       Date:  2020-04-26       Impact factor: 6.048

3.  Glaucoma Progression Analysis software compared with expert consensus opinion in the detection of visual field progression in glaucoma.

Authors:  Angelo P Tanna; Donald L Budenz; Jagadeesh Bandi; William J Feuer; Robert M Feldman; Leon W Herndon; Douglas J Rhee; Julia Whiteside-de Vos; Joyce Huang; Douglas R Anderson
Journal:  Ophthalmology       Date:  2011-12-02       Impact factor: 12.079

4.  Effect of Continuous Glucose Monitoring Accuracy on Clinicians' Retrospective Decision Making in Diabetes: A Pilot Study.

Authors:  Zeinab Mahmoudi; Mette Dencker Johansen; Hanne Holdflod Nørgaard; Steen Andersen; Ulrik Pedersen-Bjergaard; Lise Tarnow; Jens Sandahl Christiansen; Ole Hejlesen
Journal:  J Diabetes Sci Technol       Date:  2015-06-08

5.  Optical Coherence Tomography Angiography of the Peripapillary Retina in Glaucoma.

Authors:  Liang Liu; Yali Jia; Hana L Takusagawa; Alex D Pechauer; Beth Edmunds; Lorinna Lombardi; Ellen Davis; John C Morrison; David Huang
Journal:  JAMA Ophthalmol       Date:  2015-09       Impact factor: 7.389

6.  Detecting glaucomatous change in visual fields: Analysis with an optimization framework.

Authors:  Siamak Yousefi; Michael H Goldbaum; Ehsan S Varnousfaderani; Akram Belghith; Tzyy-Ping Jung; Felipe A Medeiros; Linda M Zangwill; Robert N Weinreb; Jeffrey M Liebmann; Christopher A Girkin; Christopher Bowd
Journal:  J Biomed Inform       Date:  2015-10-09       Impact factor: 6.317

7.  Pointwise Methods to Measure Long-term Visual Field Progression in Glaucoma.

Authors:  Diana Salazar; Esteban Morales; Alessandro Rabiolo; Vicente Capistrano; Mark Lin; Abdelmonem A Afifi; Fei Yu; Kouros Nouri-Mahdavi; Joseph Caprioli
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

8.  Comparison of Methods to Detect and Measure Glaucomatous Visual Field Progression.

Authors:  Alessandro Rabiolo; Esteban Morales; Lilian Mohamed; Vicente Capistrano; Ji Hyun Kim; Abdelmonem Afifi; Fei Yu; Anne L Coleman; Kouros Nouri-Mahdavi; Joseph Caprioli
Journal:  Transl Vis Sci Technol       Date:  2019-09-11       Impact factor: 3.283

9.  Detecting changes in retinal function: Analysis with Non-Stationary Weibull Error Regression and Spatial enhancement (ANSWERS).

Authors:  Haogang Zhu; Richard A Russell; Luke J Saunders; Stefano Ceccon; David F Garway-Heath; David P Crabb
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

10.  A Statistical Model to Analyze Clinician Expert Consensus on Glaucoma Progression using Spatially Correlated Visual Field Data.

Authors:  Joshua L Warren; Jean-Claude Mwanza; Angelo P Tanna; Donald L Budenz
Journal:  Transl Vis Sci Technol       Date:  2016-08-31       Impact factor: 3.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.